http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016519131-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1767 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2014-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016519131-A |
| titleOfInvention | Use of rodentia recombinant calreticulin to induce expression of interleukin-10 |
| abstract | The present invention relates to the use of a recombinant protein that induces the expression of interleukin-10. This protein is arboretum recombinant calreticulin (rTsCRT) and is formulated in physiological glucose solution to be administered orally or parenterally. The recombinant protein expressed without post-translational modification by the method of expression and purification of rTsCRT of the present invention has an immunomodulatory effect and stimulates the transcription level of mRNA encoding IL-4 cytokine and IL-10 cytokine Can do. The expression of rTsCRT was performed in an untagged E. coli system, but this expression can be applied to any expression system, whether it is a prokaryotic cell or a eukaryotic cell. This production of rTsCRT is intended for use in the treatment of local and systemic inflammatory diseases. |
| priorityDate | 2013-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 219.